CD19 and acute lymphoblastic leukemia: We demonstrate that survival is vastly improved in mice with B-ALL that have been treated with a CD19-targeted cell therapy as a supplement to cytotoxic chemotherapy in comparison to mice treated with cytotoxic chemotherapy alone.